

Athena Philis-Tsimikas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4304575/publications.pdf>

Version: 2024-02-01

46
papers

2,709
citations

304743

22
h-index

233421

45
g-index

46
all docs

46
docs citations

46
times ranked

2490
citing authors

#	ARTICLE	IF	CITATIONS
1	Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 2464-2471.	8.6	305
2	Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly Controlled Type 2 Diabetes. <i>Clinical Therapeutics</i> , 2006, 28, 1569-1581.	2.5	258
3	REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 1 Diabetes. <i>Diabetes Care</i> , 2017, 40, 538-545.	8.6	230
4	Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 2397.	7.4	191
5	Improvement in Diabetes Care of Underinsured Patients Enrolled in Project Dulce: A community-based, culturally appropriate, nurse case management and peer education diabetes care model. <i>Diabetes Care</i> , 2004, 27, 110-115.	8.6	190
6	Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 33.	7.4	179
7	Peer-Led Diabetes Education Programs in High-Risk Mexican Americans Improve Glycemic Control Compared With Standard Approaches. <i>Diabetes Care</i> , 2011, 34, 1926-1931.	8.6	177
8	Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1). <i>Diabetes Care</i> , 2017, 40, 943-950.	8.6	148
9	Dulce Digital: An mHealth SMS-Based Intervention Improves Glycemic Control in Hispanics With Type 2 Diabetes. <i>Diabetes Care</i> , 2017, 40, 1349-1355.	8.6	118
10	Outcomes of Project Dulce: A Culturally Specific Diabetes Management Program. <i>Annals of Pharmacotherapy</i> , 2005, 39, 817-822.	1.9	74
11	Cost-Effectiveness of Diabetes Case Management for Low-Income Populations. <i>Health Services Research</i> , 2007, 42, 1943-1959.	2.0	72
12	A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 1226-1242.	2.2	69
13	Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1148-1155.	4.4	68
14	Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial. <i>Diabetologia</i> , 2020, 63, 698-710.	6.3	58
15	Glucose as the Fifth Vital Sign: A Randomized Controlled Trial of Continuous Glucose Monitoring in a Non-ICU Hospital Setting. <i>Diabetes Care</i> , 2020, 43, 2873-2877.	8.6	54
16	Dulce Wireless Tijuana: A Randomized Control Trial Evaluating the Impact of Project Dulce and Short-Term Mobile Technology on Glycemic Control in a Family Medicine Clinic in Northern Mexico. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 240-251.	4.4	53
17	Glycemic control among Latinos with type 2 diabetes: The role of social-environmental support resources.. <i>Health Psychology</i> , 2011, 30, 251-258.	1.6	51
18	Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter 2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1399-1408.	4.4	48

#	ARTICLE	IF	CITATIONS
19	Improving Treatment of Depression Among Latinos With Diabetes Using Project Dulce and IMPACT. <i>Diabetes Care</i> , 2008, 31, 1324-1326.	8.6	44
20	Insulin Degludec Once-Daily in Type 2 Diabetes: Simple or Step-Wise Titration (BEGIN: Once Simple Use). <i>Advances in Therapy</i> , 2013, 30, 607-622.	2.9	42
21	Dulce Mothers: an intervention to reduce diabetes and cardiovascular risk in Latinas after gestational diabetes. <i>Translational Behavioral Medicine</i> , 2014, 4, 18-25.	2.4	34
22	Initiating Basal Insulin Therapy in Type 2 Diabetes: Practical Steps to Optimize Glycemic Control. <i>American Journal of Medicine</i> , 2013, 126, S21-S27.	1.5	30
23	Benefit of Continuous Glucose Monitoring in Reducing Hypoglycemia Is Sustained Through 12 Months of Use Among Older Adults with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 424-434.	4.4	27
24	Innovative Diabetes Interventions in the U.S. Hispanic Population. <i>Diabetes Spectrum</i> , 2019, 32, 295-301.	1.0	22
25	Efficacy and Safety of Degludec Compared to Glargine 300 Units/mL in Insulin-Experienced Patients With Type 2 Diabetes: Trial Protocol Amendment (NCT03078478). <i>Journal of Diabetes Science and Technology</i> , 2019, 13, 498-506.	2.2	20
26	Implementing Community-Based Diabetes Programs: The Scripps Whittier Diabetes Institute Experience. <i>Current Diabetes Reports</i> , 2014, 14, 462.	4.2	18
27	Precision, Accuracy, and User Acceptance of the OneTouch SelectSimple Blood Glucose Monitoring System. <i>Journal of Diabetes Science and Technology</i> , 2011, 5, 1602-1609.	2.2	17
28	Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 223-230.	2.3	17
29	An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update). <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2181-2195.	1.8	15
30	Care Team Integration in Primary Care Improves One-Year Clinical and Financial Outcomes in Diabetes: A Case for Value-Based Care. <i>Population Health Management</i> , 2020, 23, 467-475.	1.7	13
31	When insulin degludec enhances quality of life in patients with type 2 diabetes: a qualitative investigation. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 87.	2.4	10
32	Does Diabetes Distress Influence Clinical Response to an mHealth Diabetes Self-Management Education and Support Intervention?. <i>The Diabetes Educator</i> , 2020, 46, 289-296.	2.5	7
33	100 years on: the impact of the discovery of insulin on clinical outcomes. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002373.	2.8	7
34	Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes. <i>Patient Preference and Adherence</i> , 2008, 2, 323.	1.8	6
35	Glycemic Control With Insulin Glargine as Part of an Ethnically Diverse, Community-Based Diabetes Management Program. <i>American Journal of Therapeutics</i> , 2006, 13, 466-472.	0.9	5
36	The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 779-787.	4.4	5

#	ARTICLE	IF	CITATIONS
37	Dulce Digital-Me: protocol for a randomized controlled trial of an adaptive mHealth intervention for underserved Hispanics with diabetes. <i>Trials</i> , 2022, 23, 80.	1.6	5
38	Teen Peer Educators and Diabetes Knowledge of Low-Income Fifth Grade Students. <i>Journal of Community Health</i> , 2011, 36, 23-26.	3.8	4
39	Medical assistant health coaching (â€œMACâ€™) for type 2 diabetes in diverse primary care settings: A pragmatic, cluster-randomized controlled trial protocol. <i>Contemporary Clinical Trials</i> , 2021, 100, 106164.	1.8	4
40	Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine <scp>U300</scp> in people with type 2 diabetes: A post hoc analysis of the <scp>CONCLUDE</scp> trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 332-336.	4.4	4
41	Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidaseâ€™4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 658-668.	4.4	3
42	Efficacy and Safety of Fast-Acting Insulin Aspart in People with Type 1 Diabetes Using Carbohydrate Counting: A Post Hoc Analysis of Two Randomised Controlled Trials. <i>Diabetes Therapy</i> , 2019, 10, 1029-1041.	2.5	2
43	Innovative Solutions to Care for Individuals With Diabetes in Underserved Populations. <i>Diabetes Spectrum</i> , 2019, 32, 291-292.	1.0	2
44	Digital health tools to promote diabetes education and management of cardiovascular risk factors among under-resourced populations. <i>Cardiovascular Digital Health Journal</i> , 2021, 2, 298-300.	1.3	2
45	Process evaluation of a medical assistant health coaching intervention for type 2 diabetes in diverse primary care settings. <i>Translational Behavioral Medicine</i> , 2021, , .	2.4	1
46	Novel Approach to Inpatient Glucometric Monitoring and Variability in a Community Hospital Setting. <i>Journal of Diabetes Science and Technology</i> , 2015, 9, 246-256.	2.2	0